Sarepta’s ‘unfounded’ weakness a buying opportunity, says RBC Capital

RBC Capital analyst Brian Abrahams believes there has been some confusion coming out of an investor presentation this morning on Sarepta’s limb girdle muscular dystrophy data and on the regulatory path for microdystrophin gene therapy. After talking with the company, he believes timelines and prospects for both remain intact, views the weakness as “‘unfounded” and would use the pullback today as a buying opportunity. Abrahams maintains an Outperform rating on Sarepta shares.
https://thefly.com/landingPageNews.php?id=2844941